Roscovitine inhibits Ca V3.1 (T-type) channels by preferentially affecting closed-state inactivation

Journal of Pharmacology and Experimental Therapeutics

Volumn 340, Issue 2, 2012, Pages 463-472

  Yarotskyy, Viktor ^a   Elmslie, Keith S ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b A T STILL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL T TYPE; CYCLIN DEPENDENT KINASE; PROTEIN CAV3.1; ROSCOVITINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CA(V)3.1 PROTEIN, RAT; CALCIUM CHANNEL BLOCKING AGENT; PURINE DERIVATIVE;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL MEMBRANE DEPOLARIZATION; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG PROTEIN BINDING; EMBRYO; HUMAN; HUMAN CELL; INHIBITION KINETICS; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; WHOLE CELL; ACTION POTENTIAL; ANIMAL; CHANNEL GATING; DOSE RESPONSE; DRUG EFFECT; ELECTROPHYSIOLOGY; ELECTROSTIMULATION; GENETIC TRANSFECTION; KINETICS; PHYSIOLOGY; RAT;

ACTION POTENTIALS; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ELECTROPHYSIOLOGICAL PHENOMENA; HEK293 CELLS; HUMANS; ION CHANNEL GATING; KINETICS; MEMBRANE POTENTIALS; PURINES; RATS; TRANSFECTION;

EID: 84856013870     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.187104     Document Type: Article

References (47)

1. Arcangeli A (2005) Expression and role of hERG channels in cancer cells. Novartis Found Symp 266:225-232; discussion 232-234.
2. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, et al. (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96:29-37. (Pubitemid 46094635)
3. Bossu JL and Feltz A (1986) Inactivation of the low-threshold transient calcium current in rat sensory neurones: evidence for a dual process. J Physiol 376:341-357.
4. V2.2) deactivation by the cyclin-dependent kinase inhibitor roscovitine. Biophys J 89:1681-1691.
5. Buraei Z and Elmslie KS (2008) The separation of antagonist from agonist effects of trisubstituted purines on CaV2.2 (N-type) channels. J Neurochem 105:1450-1461. (Pubitemid 351590805)
6. V2 and Kv channels by binding to the open state. Neuropharmacology 52:883-894.
7. Catterall WA, Perez-Reyes E, Snutch TP, and Striessnig J (2005) International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 57:411-425. (Pubitemid 43036432)
8. Cho S and Meriney SD (2006) The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur J Neurosci 23:3200-3208.
9. De Azevedo WF, Leclerc S, Meijer L, Havlicek L, Strnad M, and Kim SH (1997) Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. Eur J Biochem 243:518-526. (Pubitemid 27060442)
10. V3.1 T-type calcium current by aliphatic alcohols. Neuropharmacology 59:58-69.
11. Elmslie KS (2004) Calcium channel blockers in the treatment of disease. J Neurosci Res 75:733-741.
12. Fischer PM and Gianella-Borradori A (2003) CDK inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 12:955-970. (Pubitemid 36722448)
13. Ganapathi SB, Kester M, and Elmslie KS (2009) State-dependent block of HERG potassium channels by R-roscovitine: implications for cancer therapy. Am J Physiol Cell Physiol 296:C701-C710.
14. Gray LS and Macdonald TL (2006) The pharmacology and regulation of T type calcium channels: new opportunities for unique therapeutics for cancer. Cell Calcium 40:115-120. (Pubitemid 43942296)
15. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, Peschel C, and Decker T (2004) Cyclin-dependent kinase inhibitor roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 18:747-755. (Pubitemid 38500193)
16. 2+ channel blockers suppress the growth of human cancer cells. Bioorg Med Chem Lett 18:3899-3901.
17. 2+ current in rat clonal (GH3) pituitary cells. J Neurophysiol 68:213-232.
18. Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682-690.
19. Howitz KT and Sinclair DA (2008) Xenohormesis: sensing the chemical cues of other species. Cell 133:387-391. (Pubitemid 351622015)
20. Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, Su P, Jevtovic-Todorovic V, and Todorovic SM (2008) Up-regulation of the T-type calcium current in small rat sensory neurons after chronic constrictive injury of the sciatic nerve. J Neurophysiol 99:3151-3156.
21. Jones SW (1989) On the resting potential of isolated frog sympathetic neurons. Neuron 3:153-161.
22. Lee JY, Park SJ, Park SJ, Lee MJ, Rhim H, Seo SH, and Kim KS (2006) Growth inhibition of human cancer cells in vitro by T-type calcium channel blockers. Bioorg Med Chem Lett 16:5014-5017. (Pubitemid 44247713)
23. 2+ channels inhibits human ovarian cancer cell proliferation. Cancer Invest 29:339-346.
24. 2+ channel in hepatocellular carcinoma cell proliferation. Oncol Rep 22:1229-1235.
25. Llinás R, Steinberg IZ, and Walton K (1981) Relationship between presynaptic calcium current and postsynaptic potential in squid giant synapse. Biophys J 33:323-351. (Pubitemid 11191467)
26. Llinás R, Sugimori M, and Simon SM (1982) Transmission by presynaptic spike-like depolarization in the squid giant synapse. Proc Natl Acad Sci U S A 79:2415-2419. (Pubitemid 12161333)
27. 2+ channel expression in human esophageal carcinomas: a functional role in proliferation. Cell Calcium 43:49-58.
28. Martin RL, Lee JH, Cribbs LL, Perez-Reyes E, and Hanck DA (2000) Mibefradil block of cloned T-type calcium channels. J Pharmacol Exp Ther 295:302-308.
29. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, Paglierani M, Pollo B, Taddei GL, Gallina P, et al. (2005) hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 93:781-792. (Pubitemid 41486438)
30. McDonough SI and Bean BP (1998) Mibefradil inhibition of T-type calcium channels in cerebellar purkinje neurons. Mol Pharmacol 54:1080-1087. (Pubitemid 29002052)
31. Meijer L, Borgne A, Mulner O, Chong JP, Blow JJ, Inagaki N, Inagaki M, Delcros JG, and Moulinoux JP (1997) Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243:527-536. (Pubitemid 27060443)
32. Pardo LA (2004) Voltage-gated potassium channels in cell proliferation. Physiology (Bethesda) 19:285-292.
33. Pardo LA, Contreras-Jurado C, Zientkowska M, Alves F, and Stühmer W (2005) Role of voltage-gated potassium channels in cancer. J Membr Biol 205:115-124. (Pubitemid 41803688)
34. Perez-Reyes E (2003) Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 83:117-161.
35. + channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110:1238-1250.
36. + channel: target and antitarget strategies in drug development. Pharmacol Res 57:181-195.
37. Serrano JR, Perez-Reyes E, and Jones SW (1999) State-dependent inactivation of the α1G T-type calcium channel. J Gen Physiol 114:185-201. (Pubitemid 29380149)
38. 2+ channels suppresses human breast cancer cell proliferation. Cancer Lett 267:116-124.
39. Taylor JT, Zeng XB, Pottle JE, Lee K, Wang AR, Yi SG, Scruggs JA, Sikka SS, and Li M (2008b) Calcium signaling and T-type calcium channels in cancer cell cycling. World J Gastroenterol 14:4984-4991.
40. Uebele VN, Gotter AL, Nuss CE, Kraus RL, Doran SM, Garson SL, Reiss DR, Li Y, Barrow JC, Reger TS, et al. (2009) Antagonism of T-type calcium channels inhibits high-fat diet-induced weight gain in mice. J Clin Invest 119:1659-1667.
41. Wesierska-Gadek J, Schmitz ML, and Ranftler C (2007) Roscovitine- activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100:865-874.
42. Yang K, Bai H, Ouyang Q, Lai L, and Tang C (2008) Finding multiple target optimal intervention in disease-related molecular network. Mol Syst Biol 4:228.
43. Yarotskyy V and Elmslie KS (2007) Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (CaV1.2) calcium channels. Br J Pharmacol 152:386-395. (Pubitemid 47511263)
44. V1.2) sites that separately affect activation and inactivation. J Biol Chem 285:43-53.
45. V1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation. J Physiol 587:551-565.
46. Yazawa M, Hsueh B, Jia X, Pasca AM, Bernstein JA, Hallmayer J, and Dolmetsch RE (2011) Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471:230-234.
47. 2+ channel isoform in insulin-secreting cells. Diabetes 49:59-64.